TABLE 2.

Properties of DOX-HCQ-SLN

	Formulation	PS (nm)	PDI	Zeta potential (mV)	Doxycycline encapsulation (%)	Hydroxychloroquine encapsulation (%)	Doxycycline loading (%)	Hydroxychloroquine loading (%)
Before lyophilization	F1	114.3	0.246	−21.5	95.5	90.1	15.4	15.1
	F2	155.8	0.294	−15.6	98.8	95.0	14.1	13.2
	F3	280.4	0.452	−19.0	96.2	88.3	13.2	12.9
	F4	221.1	0.333	−22.2	95.3	85.6	16.9	15.5
	F5	210.3	0.343	−19.5	97.3	91.6	14.8	11.1
	F6	200.8	0.299	−17.7	92.4	85.8	12.2	10.0
	F7	293.4	0.390	−15.9	91.3	89.9	14.6	9.9
	F8	430.8	0.456	−19.9	95.9	91.6	11.3	9.8
After lyophilization	F1	120.4	0.270	22.2	93.2	90.2	15.3	14.3
	F2	170.9	0.365	16.6	95.5	88.3	10.2	9.6
	F3	300.5	0.456	20.5	90.2	84.7	14.9	11.3
	F4	246.8	0.398	25.6	95.8	92.5	19.1	16.3
	F5	214.3	0.385	−18.7	96.1	90.0	14.5	9.5
	F6	232.1	0.342	−13.9	93.4	87.9	12.1	10.9
	F7	302.5	0.401	−16.9	90.2	88.3	13.2	11.8
	F8	436.8	0.55	−21.5	91.1	87.6	11.9	9.8

They mean that optimum condition for formulation.